For Dr. Jerry Zhengyi Wang the journey to discovery started with a quest for a new way to leverage the immune system against cancer. His basic research on the role of macrophages in the anti-tumor immunity led him to CD47, which acts as a “don’t eat me” signal that enables cancer cells to evade detection.
Dr. Wang is among the I-Mab scientists behind lemzoparlimab, a highly differentiated anti-CD47 monoclonal antibody for the treatment of multiple cancers. The antibody is at the center of the global strategic partnership between I-Mab and the Chicago-based biopharma company AbbVie, announced last September and valued at about $3 billion. The potential of his team’s work to transform the treatment of cancer patients fueled an intensely focused investigation that began in 2016. And the entire process has been an incredibly fulfilling one, according to Dr. Wang, Vice President of Discovery.
"break" - Google News
January 06, 2021 at 07:00PM
https://ift.tt/35f00o9
Tim Lu's quest to break new cell therapy ground with gene circuits gets Bayer's backing in a big new financing round - Endpoints News
"break" - Google News
https://ift.tt/3dlJq82
Bagikan Berita Ini
0 Response to "Tim Lu's quest to break new cell therapy ground with gene circuits gets Bayer's backing in a big new financing round - Endpoints News"
Post a Comment